Trevi Therapeutics, Inc. TRVI Interest Expense
Discontinued — last reported Q4 '25
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Trevi Therapeutics, Inc.’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s interest expense?
- Trevi Therapeutics, Inc. (TRVI) reported interest expense of $0 in Q4 2025.
- How has Trevi Therapeutics, Inc.'s interest expense changed year-over-year?
- Trevi Therapeutics, Inc.'s interest expense decreased by 100.0% year-over-year, from $1K to $0.
- What is the long-term trend for Trevi Therapeutics, Inc.'s interest expense?
- Over 4 years (2021 to 2025), Trevi Therapeutics, Inc.'s interest expense has grown at a -100.0% compound annual growth rate (CAGR), from $1.2M to $0.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.